The latest price target for Sarepta Therapeutics (NASDAQ:SRPT) was reported by Guggenheim on November 7, 2024. The analyst firm set a price target for $150.00 expecting SRPT to rise to within 12 months (a possible 41.51% upside). 68 analyst firms have reported ratings in the last year.

The latest analyst rating for Sarepta Therapeutics (NASDAQ:SRPT) was provided by Guggenheim, and Sarepta Therapeutics maintained their buy rating.

The last upgrade for Sarepta Therapeutics Inc happened on November 7, 2024 when Cantor Fitzgerald raised their price target to $167. Cantor Fitzgerald previously had a neutral for Sarepta Therapeutics Inc.

The last downgrade for Sarepta Therapeutics Inc happened on June 26, 2024 when Citigroup changed their price target from $172 to $176 for Sarepta Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sarepta Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sarepta Therapeutics was filed on November 7, 2024 so you should expect the next rating to be made available sometime around November 7, 2025.

While ratings are subjective and will change, the latest Sarepta Therapeutics (SRPT) rating was a maintained with a price target of $148.00 to $150.00. The current price Sarepta Therapeutics (SRPT) is trading at is $106.00, which is out of the analyst’s predicted range.